Preliminary Data of the Safety and Immunogenicity Protocol of Vaccination for SARS-CoV 2 in Solid Organ Transplant Patients in Argentina
1Nephrology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2Inmunology, INBIRS CONICET, Buenos Aires, Argentina, 3Infectology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 4Hepatology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 5Cardiology, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 6Nephrology, IOT Clinica de Nefrologia, Misiones, Argentina, 7Nephrology, Hospital El Cruce - Nestor Kirchner, Buenos Aires, Argentina
Meeting: 2022 American Transplant Congress
Abstract number: 1624
Keywords: Antibodies, COVID-19, Kidney transplantation, Vaccination
Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)
Session Information
Session Name: All Infections (Excluding Kidney & Viral Hepatitis) IV
Session Type: Poster Abstract
Date: Tuesday, June 7, 2022
Session Time: 7:00pm-8:00pm
Presentation Time: 7:00pm-8:00pm
Location: Hynes Halls C & D
*Purpose: To evaluate the safety and generation rate of Ab anti spike rate in SOT patients at 28 and 90 days after completing the Covid 19 vaccination scheme.
*Methods: Multicenter prospective study in SOT with a complete vaccination scheme who agreed to participate in the study . Demographic , vaccination: schedule; time; adverse effects and transplant variables were collected. The generation rate of anti-spike antibodies was evaluated by the COVIDAR-IgG method at the Universidad de Buenos Aires School of Medicine.
*Results: 113 SOT patients were included (September 6th to October 4th). Median age was 53 (IQR 42.5-63, women 36.8%). Transplant type: 72.8% renal , 13.1% cardiac, 12.3% liver, 0.9% pancreas and 0.9% lung. Deceased donors 71.1%. The median time after transplantation to vaccination was 65 months (IQR 30 120 R 2-429). Only 7% of patients developed rejection within the year prior to vaccination and no patient rejected post vaccination. 74.3% (n 84) had triple immunosuppressive maintenance regimen (steroids + calcineurin inhibitors (ICN) + antiproliferative), 24 pts (21.1%) double regimen WITHOUT steroids and 5 (4.3%) monotherapy with IC. Vaccination schedule: Sputnik 14.5%, Sputnik-Astrazeneca 4.4%, Sputnik-Moderna 28.9%, Sinopharm 3.5%, Astrazeneca 34.2%. Vaccine-related adverse events were observed in 18.4% of patients, 82% were mild. 40% of SOT responded with Anti-spike Ab , with a lower response rate in kidney transplantation p <0.0007 RR 0.48 (0.32-0.71) and use of triple immunosuppressive maintenance regimen p <0.00009 RR 0.419 (0.26 -0.66). Patients previously infected with Covid-19 prior to vaccine (11.45% pts), had a higher response rate p <0.0001 RR 2.58 (1.90-3.51).No patients developed COVID-19 after vaccination.
*Conclusions: In our SOT population, a lower generation rate of anti-spike Ab was observed, compared to the reported in the general population. Renal Tx and the triple IS regimen were associated with a lower response rate. Covid-19 prior to vaccination was associated with a higher antibody response to the vaccine.
To cite this abstract in AMA style:
Cortez SKVillamil, Geffner JR, Barcan LA, Remersano P, Smud A, Villamil A, Imperiali NC, Groppa SR, Mombelli CA, Muñoz VASuarez, Belziti C, Marcelo F, Pietrantonio SDi, Diez GJRosa, Giordani MC. Preliminary Data of the Safety and Immunogenicity Protocol of Vaccination for SARS-CoV 2 in Solid Organ Transplant Patients in Argentina [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/preliminary-data-of-the-safety-and-immunogenicity-protocol-of-vaccination-for-sars-cov-2-in-solid-organ-transplant-patients-in-argentina/. Accessed November 21, 2024.« Back to 2022 American Transplant Congress